Overview

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

Status:
Completed
Trial end date:
2016-07-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics of alisertib in adult participants with cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.